|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.
|
|
2
|
Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H,
Zhang Z, Li C and Li Y: Metformin and temozolomide act
synergistically to inhibit growth of glioma cells and glioma stem
cells in vitro and in vivo. Oncotarget. 6:32930–32943. 2015.
|
|
3
|
Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao
G, Chen Y, Li Y and Zhao G: NVP-BEZ235, a novel dual PI3K-mTOR
inhibitor displays anti-glioma activity and reduces chemoresistance
to temozolomide in human glioma cells. Cancer Lett. 367:58–68.
2015.
|
|
4
|
Chen R, Smith-Cohn M, Cohen AL and Colman
H: Glioma subclassifications and their clinical significance.
Neurotherapeutics. 14:284–297. 2017.
|
|
5
|
Korshunov DA, Kondakova IV and Shashova
EE: Modern perspective on metabolic reprogramming in malignant
neoplasms. Biochemistry (Mosc). 84:1129–1142. 2019.
|
|
6
|
Tarrado-Castellarnau M, de Atauri P and
Cascante M: Oncogenic regulation of tumor metabolic reprogramming.
Oncotarget. 7:62726–62753. 2016.
|
|
7
|
Koundouros N and Poulogiannis G:
Reprogramming of fatty acid metabolism in cancer. Br J Cancer.
122:4–22. 2020.
|
|
8
|
Cheng X, Li J and Guo D: SCAP/SREBPs are
central players in lipid metabolism and novel metabolic targets in
cancer therapy. Curr Top Med Chem. 18:484–493. 2018.
|
|
9
|
Williams KJ, Argus JP, Zhu Y, Wilks MQ,
Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN,
et al: An essential requirement for the SCAP/SREBP signaling axis
to protect cancer cells from lipotoxicity. Cancer Res.
73:2850–2862. 2013.
|
|
10
|
Nohturfft A, Yabe D, Goldstein JL, Brown
MS and Espenshade PJ: Regulated step in cholesterol feedback
localized to budding of SCAP from ER membranes. Cell. 102:315–323.
2000.
|
|
11
|
Mulligan LM: GDNF and the RET receptor in
cancer: New insights and therapeutic potential. Front Physiol.
9:18732019.
|
|
12
|
Zhang L, Wang D, Han X, Tang F and Gao D:
Mechanism of methylation and acetylation of high GDNF transcription
in glioma cells: A review. Heliyon. 5:e019512019.
|
|
13
|
Shabtay-Orbach A, Amit M, Binenbaum Y,
Na'ara S and Gil Z: Paracrine regulation of glioma cells invasion
by astrocytes is mediated by glial-derived neurotrophic factor. Int
J Cancer. 137:1012–1020. 2015.
|
|
14
|
Kawai K and Takahashi M: Intracellular RET
signaling pathways activated by GDNF. Cell Tissue Res. 382:113–123.
2020.
|
|
15
|
Wiesenhofer B, Stockhammer G, Kostron H,
Maier H, Hinterhuber H and Humpel C: Glial cell line-derived
neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are
strongly expressed in human gliomas. Acta Neuropathol. 99:131–137.
2000.
|
|
16
|
Zhang BL, Dong FL, Guo TW, Gu XH, Huang LY
and Gao DS: MiRNAs Mediate GDNF-induced proliferation and migration
of glioma cells. Cell Physiol Biochem. 44:1923–1938. 2017.
|
|
17
|
Liu XF, Tang CX, Zhang L, Tong SY, Wang Y,
Abdulrahman AA, Ji GQ, Gao Y, Gao DS and Zhang BL: Down-Regulated
CUEDC2 Increases GDNF expression by stabilizing CREB through
reducing its ubiquitination in glioma. Neurochem Res. 45:2915–2925.
2020.
|
|
18
|
Ng WH, Wan GQ, Peng ZN and Too HP: Glial
cell-line derived neurotrophic factor (GDNF) family of ligands
confer chemoresistance in a ligand-specific fashion in malignant
gliomas. J Clin Neurosci. 16:427–436. 2009.
|
|
19
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and
Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med.
19:1997–2007. 2020.
|
|
20
|
Knebel B, Lehr S, Hartwig S, Haas J, Kaber
G, Dicken HD, Susanto F, Bohne L, Jacob S, Nitzgen U, et al:
Phosphorylation of sterol regulatory element-binding protein
(SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism
and the secretome of human liver cell line HepG2. Arch Physiol
Biochem. 120:216–227. 2014.
|
|
21
|
Liu H, Ma Q and Li J: High glucose
promotes cell proliferation and enhances GDNF and RET expression in
pancreatic cancer cells. Mol Cell Biochem. 347:95–101. 2011.
|
|
22
|
Ruan M, Liu M, Dong Q and Chen L: Iodide-
and glucose-handling gene expression regulated by sorafenib or
cabozantinib in papillary thyroid cancer. J Clin Endocrinol Metab.
100:1771–1779. 2015.
|
|
23
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016.
|
|
24
|
Yu Z, Chen Y, Wang S, Li P, Zhou G and
Yuan Y: Inhibition of NF-κB results in anti-glioma activity and
reduces temozolomide-induced chemoresistance by down-regulating
MGMT gene expression. Cancer Lett. 428:77–89. 2018.
|
|
25
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010.
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
27
|
Nohturfft A, Brown MS and Goldstein JL:
Topology of SREBP cleavage-activating protein, a polytopic membrane
protein with a sterol-sensing domain. J Biol Chem. 273:17243–17250.
1998.
|
|
28
|
Cheng C, Ru P, Geng F, Liu J, Yoo JY, Wu
X, Cheng X, Euthine V, Hu P, Guo JY, et al: Glucose-Mediated
N-glycosylation of SCAP Is Essential for SREBP-1 activation and
tumor growth. Cancer Cell. 28:569–581. 2015.
|
|
29
|
Akella NM, Ciraku L and Reginato MJ:
Fueling the fire: Emerging role of the hexosamine biosynthetic
pathway in cancer. BMC Biol. 17:522019.
|
|
30
|
Semenza GL: HIF-1: Upstream and downstream
of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010.
|
|
31
|
Kamisuki S, Mao Q, Abu-Elheiga L, Gu Z,
Kugimiya A, Kwon Y, Shinohara T, Kawazoe Y, Sato S, Asakura K, et
al: A small molecule that blocks fat synthesis by inhibiting the
activation of SREBP. Chem Biol. 16:882–892. 2009.
|
|
32
|
Gholkar AA, Cheung K, Williams KJ, Lo YC,
Hamideh SA, Nnebe C, Khuu C, Bensinger SJ and Torres JZ: Fatostatin
inhibits cancer cell proliferation by affecting mitotic microtubule
spindle assembly and cell division. J Biol Chem. 291:17001–17008.
2016.
|
|
33
|
Xue L, Qi H, Zhang H, Ding L, Huang Q,
Zhao D, Wu BJ and Li X: Targeting SREBP-2-regulated mevalonate
metabolism for cancer therapy. Front Oncol. 10:15102020.
|
|
34
|
Cheng C, Geng F, Cheng X and Guo D: Lipid
metabolism reprogramming and its potential targets in cancer.
Cancer Commun (Lond). 38:272018.
|
|
35
|
Ayanlaja AA, Zhang B, Ji G, Gao Y, Wang J,
Kanwore K and Gao D: The reversible effects of glial cell
line-derived neurotrophic factor (GDNF) in the human brain. Semin
Cancer Biol. 53:212–222. 2018.
|
|
36
|
Mu P, Liu Y, Jiang S, Gao J, Sun S, Li L
and Gao D: Glial cell line-derived neurotrophic factor alters lipid
composition and protein distribution in MPP+-injured differentiated
SH-SY5Y cells. J Cell Physiol. 235:9347–9360. 2020.
|
|
37
|
Yu ZQ, Zhang BL, Ren QX, Wang JC, Yu RT,
Qu DW, Liu ZH, Xiong Y and Gao DS: Changes in transcriptional
factor binding capacity resulting from promoter region methylation
induce aberrantly high GDNF expression in human glioma. Mol
Neurobiol. 48:571–580. 2013.
|
|
38
|
Cruceru ML, Enciu AM, Popa AC, Albulescu
R, Neagu M, Tanase CP and Constantinescu SN: Signal transduction
molecule patterns indicating potential glioblastoma therapy
approaches. Onco Targets Ther. 6:1737–1749. 2013.
|
|
39
|
McPherson R and Gauthier A: Molecular
regulation of SREBP function: The Insig-SCAP connection and
isoform-specific modulation of lipid synthesis. Biochem Cell Biol.
82:201–211. 2004.
|
|
40
|
Zhu Z, Zhao X, Zhao L, Yang H, Liu L, Li
J, Wu J, Yang F, Huang G and Liu J: p54(nrb)/NONO regulates lipid
metabolism and breast cancer growth through SREBP-1A. Oncogene.
35:1399–1410. 2016.
|
|
41
|
Nagao A, Kobayashi M, Koyasu S, Chow CCT
and Harada H: HIF-1-dependent reprogramming of glucose metabolic
pathway of cancer cells and its therapeutic significance. Int J Mol
Sci. 20:2382019.
|
